Last reviewed · How we verify
Dioxone (DIETHADIONE)
Dioxone (generic name: DIETHADIONE) is a drug. It is currently in Phase 2 development.
Dioxone is a small molecule that works by binding to specific biological molecules to produce a therapeutic effect.
Dioxone, also known as Diethadione, is a small molecule compound with unknown target and drug class. Its commercial status is unclear, and it is not known whether it is FDA-approved or off-patent. As a small molecule, it is likely to work by interacting with specific biological molecules to produce a therapeutic effect. However, without more information, it is difficult to determine its exact mechanism of action or approved indications. Further research is needed to fully understand the properties and uses of Dioxone.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | DIETHADIONE |
|---|---|
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Mechanism of action
Imagine Dioxone as a key that fits into a lock on a specific protein. When it binds, it can either turn the protein on or off, or change the way it works, which can help to treat a particular disease or condition. This is a simplified explanation of how small molecules like Dioxone can work to produce a therapeutic effect.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dioxone CI brief — competitive landscape report
- Dioxone updates RSS · CI watch RSS
Frequently asked questions about Dioxone
What is Dioxone?
How does Dioxone work?
What is the generic name of Dioxone?
What development phase is Dioxone in?
Related
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing